Trials / Completed
CompletedNCT07363434
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
RESONATE Study: Real-world Outcomes With Ribociclib in Indian Patients With HR+, HER2- Advanced Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 335 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC). This study used secondary data sources, i.e., paper-based records; electronic medical records (EMRs); and other sources, such as radiology reports, pathology reports, and examination/clinician notes related to aBC, from clinics/hospitals across 18 sites in India. Aggregated data of anonymized patients treated with ribociclib plus endocrine therapy (ET) by the approved indication between June 2018 and December 2021 were collected and analyzed.
Conditions
Timeline
- Start date
- 2022-12-21
- Primary completion
- 2024-07-26
- Completion
- 2024-07-26
- First posted
- 2026-01-23
- Last updated
- 2026-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07363434. Inclusion in this directory is not an endorsement.